Literature DB >> 11114831

Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy.

D C Mynarcik1, M A McNurlan, R T Steigbigel, J Fuhrer, M C Gelato.   

Abstract

HIV-lipodystrophy (HIV-LD) is characterized by the loss of body fat from the limbs and face, an increase in truncal fat, insulin resistance, and hyperlipidemia, factors placing affected patients at increased risk for vascular disease. This study evaluated insulin sensitivity and inflammatory status associated with HIV-LD and provides suggestions about its etiology. Insulin sensitivity and immune activation markers were assessed in 12 control subjects and 2 HIV-positive groups, 14 without and 15 with LD syndrome. Peripheral insulin sensitivity (mostly skeletal muscle) was determined with the hyperinsulinemic-euglycemic clamp. Circulating insulin-like growth factor (IGF) binding protein-1 (IGFBP-1) and free fatty acid (FFA) levels, and their response to insulin infusion were indicative of insulin responsiveness of liver and adipose tissue, respectively. Serum levels of soluble type 2 tumor necrosis factor-alpha (TNF-alpha) receptor (sTNFR2) were used as an indicator of immune activation. HIV-LD study subjects had significantly reduced (twofold) peripheral insulin sensitivity, but normal levels of FFA and reduced levels of IGFBP-1, relative to the nonlipodystrophy groups, indicating that the loss of insulin sensitivity was more pronounced in skeletal muscle than in liver or fat. The significant loss of peripheral fat in the HIV-LD group (34%; p <.05) closely correlated with the reduced peripheral insulin sensitivity (p =. 0001). Levels of sTNFR2 were elevated in all HIV-infected study subjects, but they were significantly higher in those with lipodystrophy than without, and sTNFR2 levels strongly correlated with the reduction in insulin sensitivity (p =.0001). Loss of peripheral fat, normal levels of FFA, and reduced levels of IGFBP-1 indicate that insulin resistance in HIV-LD is distinct from type 2 diabetes and obesity. The relationship between the degree of insulin resistance and sTNFR2 levels suggests an inflammatory stimulus is contributing to the development of HIV-associated lipodystrophy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114831     DOI: 10.1097/00042560-200012010-00004

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  60 in total

Review 1.  Management of the metabolic effects of HIV and HIV drugs.

Authors:  Todd T Brown; Marshall J Glesby
Journal:  Nat Rev Endocrinol       Date:  2011-09-20       Impact factor: 43.330

Review 2.  Endocrinological aspects of HIV infection.

Authors:  F S Mirza; P Luthra; L Chirch
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

Review 3.  Adipocyte, adipose tissue, and infectious disease.

Authors:  Mahalia S Desruisseaux; Maria E Trujillo; Herbert B Tanowitz; Philipp E Scherer
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

Review 4.  HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways.

Authors:  Patrick W G Mallon; Andrew Carr; David A Cooper
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

Review 5.  Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update.

Authors:  Todd Hulgan
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

Review 6.  Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.

Authors:  Denise C Hsu; Irini Sereti
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 7.  Insulin resistance in HIV-related lipodystrophy.

Authors:  Nasser Mikhail
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

8.  The role of HIV and monocytes/macrophages in adipose tissue biology.

Authors:  Cecilia M Shikuma; Louie Mar A Gangcuangco; Deirdre A Killebrew; Daniel E Libutti; Dominic C Chow; Beau K Nakamoto; Chin Yuan Liang; Cris I P Milne; Lishomwa C Ndhlovu; Jason D Barbour; Bruce T Shiramizu; Mariana Gerschenson
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

Review 9.  Cardiovascular complications in HIV management: past, present, and future.

Authors:  Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

10.  Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study.

Authors:  Phyllis C Tien; Michael F E Schneider; Stephen R Cole; Alexandra M Levine; Mardge Cohen; Jack DeHovitz; Mary Young; Jessica E Justman
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.